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Background: Colorectal cancer (CRC) is the 3rd most common cancer worldwide and the Czech Republic has the
6th highest incidence of CRC worldwide. Large intestinal microbiota play in its etiopathogenesis important role.
Bacteriocins are proteins, produced by bacteria from the Enterobacteriaceae family. The aim of our prospective study
was to assess the colonization of large intestinal mucosa by Escherichia coli strains and to investigate their
bacteriocin production.
Methods: A total of 30 consecutive patients with colorectal adenoma, CRA (17 men, 13 women, aged 39–79, mean
age 63 ± 9), 30 patients with CRC (23 men, 7 women, aged 38–86, mean age 67 ± 11) and 20 healthy controls (9
men, 11 women, age 23–84, mean age 55 ± 15) were enrolled into prospective study. Mucosal biopsies were taken
in the caecum, transverse colon and rectum during pancolonoscopy. Microbiological culture, isolation and identification
of bacteria followed. Bacteriocin production was assessed by growth inhibition of indicator strains E. coli K12-Row, E. coli
C6 (phi), and Shigella sonnei 17. Identification of bacteriocin-encoding determinants and E. coli phylogroups was
performed using PCR methods.
Results: A total of 622 strains were isolated and further investigated. A significantly higher frequency of simultaneous
production of colicins and microcins was revealed in the group of patients with CRC, when compared to patients
with CRA, p = 0.031. A significantly higher frequency of E. coli phylogroup D was found in patients with CRC, when
compared to controls, p = 0.044. A significantly higher prevalence of bacteriocinogeny was confirmed in patients with
advanced adenoma when compared to patients with non-advanced adenoma, p = 0.010. Increasing bacteriocinogeny
was associated with an increasing stage of CRC (assessed according to TNM classification). Either E. coli phylogroup B2
or E. coli phylogroup D were isolated in biopsies of patients with right-sided CRC. A statistically higher incidence of
E. coli phylogroup B2 was found in patients with right-sided CRC when compared to patients with left-sided CRC,
p = 0.028.
Conclusions: Large intestinal mucosa of patients with more advanced colorectal neoplasia is colonized with more
virulent strains of E. coli and higher production of bacteriocins is observed in these patients when compared to those
with less advanced colorectal neoplasia.
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Colorectal cancer (CRC) is the 3rd most common cancer
having been diagnosed in nearly 1.4 million people
worldwide in 2012. The Czech Republic had the 6th
highest incidence of CRC worldwide and the age-
standardized rate per 100 000 was 38.9 in 2012 [1].
Despite previous efforts, the etiopathogenesis of CRC
has not been fully clarified yet and prevention does not
exist. Large intestinal microbiota, undoubtedly, play an
important role in the CRC pathogenesis [2,3].
Even though a considerable effort was put into the de-
velopment of new antineoplastic therapeutic strategies,
severe side effects and resistance of colon cancer cells
towards the therapy remain limiting hurdles [4,5].
Bacteriocins possess antimicrobial [6], proapoptotic [7],
and probiotic properties [8]. Although the exact role of
bacteriocins is not known on both bacterial population
level and at the level of their interaction with the
eukaryotic host, several bacteriocins posess antineoplastic
properties according to in vitro studies [9,10]. Colicins,
microcins, pyocins and pediocins belong to the bacterio-
cins with a reported antineoplastic activity [11].
Bacteriocins are produced by Escherichia coli strains
and related bacteria from the Enterobacteriaceae family
[12,13].
The aim of our prospective study was to assess whether
there are differences in E. coli colonization of the large in-
testinal mucosa between the groups tested and to investi-
gate bacteriocin production in the patients with colorectal
adenoma (CRA) and CRC.
Methods
A total of 30 consecutive patients with CRA (17 men, 13
women, aged 39–79, mean age 63 ± 9), 30 patients with
CRC (23 men, 7 women, aged 38–86, mean age 67 ± 11)
and 20 healthy controls (population with average risk for
CRC with normal endoscopic findings and with negative
history of CRA, CRC or inflammatory bowel disease; 9
men, 11 women, age 23–84, mean age 55 ± 15) were
enrolled into the prospective study.
There were 6 patients with non-advanced (N-A) CRA
and 24 patients with advanced (A) CRA. Advanced CRA
is either an adenoma with low grade dysplasia larger
than 10 mm and/or adenoma with high grade dysplasia
of any size and/or adenoma with villous component
found on histology. The group with CRC included 4 pa-
tients with right-sided CRC and 26 patients with left-sided
CRC. The border between the “left” and the “right” colon
was at the lineal flexure of the colon.
Individuals enrolled into the study were invited for the
diagnostic and/or therapeutic pancolonoscopy. The usual
bowel preparation was either polyethylene glycol or so-
dium phosphate solution. Pancolonoscopy was performed
in a standard manner under conscious sedation in allthe subjects. Video-colonoscopes Olympus 160 series
(Olympus Corp., Tokyo, Japan) were used after previous
high-level disinfection for each particular investigation
(ETD2 and ETD3 disinfectors Olympus). Mucosal biop-
sies were taken from the caecum, transverse colon and the
rectum during the procedure in all the patients/healthy
controls (90 biopsies in patients with CRA, 90 biopsies in
patients with CRC and 60 biopsies in the control group).
Sterile biopsy forceps (Olympus) were used for every sin-
gle biopsy. In our previous study we verified that the inner
space of the forceps remained sterile despite the passage
of the accessory through the working channel of the endo-
scope (data not shown). Each biopsy specimen of the co-
lonic mucosa was immediately inserted into a transport
liver-enriched broth. Standard primary cultures were inocu-
lated on the blood and MacConkey agars (at 37°C for
24 hours); this was followed by a standard clone isolation.
Up to 7 different colonies of the coliform bacteria were
isolated from each sample (on the blood, MacConkey
and deoxycholate agars). Particular bacteria were pre-
cisely identified by the Vitek2 system (BioMérieux,
Marcy l’Etoile, France) and susceptibility of the strains
to the antibiotics was assessed. Together, 622 isolates
were identified: 221 in the group of patients with CRA,
151 in the healthy controls and 250 in the patients with
CRC. All the bacterial strains were frozen in cryotube
vials at −80°C appropriately.
Bacteriocinogeny (bacteriocin production) of each strain,
bacteriocinogenotypisation (determination of bacteriocin
type) and E. coli phylogroups were further investigated.
Frozen bacterial strains were streaked for single colonies
and one single colony was used for inoculation of liquid
TY medium containing tryptone (Hi-Media, Mumbai,
India) 8 g/L, yeast extract (Hi-Media) 5 g/L, and sodium
chloride 5 g/L. The agar plates (containing the 1.5% TY
agar, w/v) were subsequently inoculated by needle stab
with fresh broth cultures and the plates were incubated at
37°C for 48 hours. The bacteria were killed using chloro-
form vapours for 30 minutes. Each plate was overlaid with
a thin layer of a soft agar (0.7% TY agar, w/v) containing
107 cells/mL of an indicator strain. The plates were then
incubated at 37°C overnight. With the exception of TY
agar plates, bacteriocin production was tested on a rela-
tively unenriched agar containing a Difco™nutrient broth
(Difco Laboratories, Sparks, MD) 8 g/L, sodium chloride
5 g/L, and 1.5% (w/v) agar. Indicator strains of E. coli
K12-Row, E. coli C6 (phi) and Shigella sonnei 17 were
used for the assessment of bacteriocin production (a
zone of growth inhibition is present around the strain
tested, if the indicator strain is susceptible to the bacteri-
ocin produced by the strain tested). All these indicator
strains were from our in-house collection of strains. Bac-
teriocin production was also confirmed by PCR methods.
Bacteriocinogenotypisation and determination of E. coli
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cific primers for the detection of colicin, microcin genes
(see Tables 1 and 2 for details) and genes specific for each
E. coli phylogroup [14]. Altogether, 23 individual colicin
types (colicins A, B, D, E1-E9, Ia, Ib, Js, K, L, M, N, S4,
U, Y, 5/10) and 8 microcin types (mB17, mC7, mE492,
mH47, mJ25, mL, mM, mV) were tested in this study
[15]; see Additional file 1 for details.
Data obtained were treated statistically by means of
descriptive statistics, non-paired t-test and Fisher’s exact
test using Statistica software. The differences in bacterio-
cinogeny, colicinogeny and microcinogeny between the
groups tested were assessed by non-paired t-test (as this
was referred to the number of biopsies taken in each
group: 90 vs 90 vs 60). Fisher t-test was used for investi-
gation of differences in production of each bacteriocin
between the groups tested (as this was reffered to the
number of individuals in each group: 30 vs 30 vs 20 and
the numbers were small).
All individuals enrolled into the study were adult per-
sons. Participants were adequately informed and a written
informed consent for participation in the study including
agreement with the data and information to be published
in an anonymous way was obtained from all the enrolled
subjects. The project was approved by the Joint Ethical
Committee (Charles University in Praha, Faculty of
Medicine at Hradec Kralove & University Teaching
Hospital Hradec Kralove). For all data obtained, all per-
sonal identification information was removed in compli-
ance with the Czech laws for protection of confidentiality.
Results
Microbiological culture was performed on 240 mucosal
biopsies taken from 60 patients (30 patients with CRC,
30 patients with CRA) and 20 healthy controls. Together
622 strains were isolated and futher investigated. There
were no statistically significant differences in the frequency
of strains belonging to the Enterobacteriaceae family
between our groups investigated. A significantly higher
frequency of Escherichia coli strains was found in the
patients with CRC, when compared to the healthy con-
trols, p < 0.001; see Table 3 for details.
There was no difference in colicinogeny and microcino-
geny between the groups tested. A significantly higher
frequency of simultaneous production of colicins and
microcins was revealed in the group of patients with
CRC, when compared to patients with CRA, p = 0.031; see
Table 3 for details. A trend towards higher co-production
of colicins and microcins in the healthy controls, when
compared to the patients with CRA, was revealed, p =
0.065; see Table 3 for details. A statistically significant dif-
ference in bacteriocinogeny was found between patients
with non-advanced (N-A) and patients with advanced (A)
CRA: N-A: 7/18 (39%), A: 51/71 (72%); p = 0.010.Colicin Ia was the most commonly synthetised colicin
in all the groups tested. It was followed by the colicin Ib
in the patients with CRA and in the healthy controls. In
the patients with CRC, the colicin M belongs to the 2nd
most frequently synthetised colicin after the colicin Ia.
Colicin M was produced by 4% of patients with CRA,
10% of healthy individuals and 21% of patients with
CRC. There was a statistically significant difference in
production of colicin M between the patients with CRA
and CRC (p = 0.001) and a trend towards higher production
of colicin M in the patients with CRC, when compared to
the healthy controls, was identified; p = 0.070. Microcin
mH47 was the most frequently produced microcin in all
the groups tested. In the patients with CRA, it was followed
by microcin mV. Synthesis of microcin mM was the second
most common after microcin mH47 in the patients with
CRC and in the healthy individuals.
The lowest incidence of E. coli phylogroup A and B1
were found in the group of the patients with CRC. A sig-
nificantly higher frequency of E. coli phylogroup D was
found in the group of patients with CRC, when compared
to the healthy controls, p = 0.044. Similar frequency of E.
coli phylogroup B2 was found in all the groups tested; see
Table 3 for details. A trend towards lower frequency of E.
coli phylogroup B2 was revealed in the group of patients
with N-A CRA, when compared to the patients with A
CRA: N-A: 4/17 (24%), A: 31/60 (52%); p = 0.054. Either
E. coli phylogroup B2 or E. coli phylogroup D were iso-
lated in all biopsies, which were taken in the patients with
right-sided CRC. A statistically significant difference in
the frequency of E. coli phylogroup B2 was revealed be-
tween patients with right-sided CRC and patients with
left-sided CRC: right-sided: 9/12 (75%), left-sided: 32/78
(41%); p = 0.028.
Increasing bacteriocinogeny, colicinogeny, microcino-
geny and colicinogeny & microcinogeny was associated
with an increasing stage of CRC (assessed according to
the TNM classification), see Table 4 for details. A statisti-
cally significant difference was found in microcinogeny
between the stage 1 and stage 4: p = 0.038.
Discussion
Large intestinal microbiota, undoubtedly, play an import-
ant role in the pathogenesis of CRC [2,3]. E. coli can be
classified into 3 major groups: commensal strains, intes-
tinal pathogenic strains and extraintestinal pathogenic
strains [16,17]. Phylogenetic diversity of E. coli exists
within each subgroup [16]. Four phylogroups of E. coli
are well-known. Commensal strains usually belong to
the A or B1 phylogenetic group; pathogenic strains usu-
ally belong to B2 or D phylogroup of E. coli and they
possess more virulence factors when compared to the
commensal strains [16,18,19]. Among our groups tested,
the lowest incidence of E. coli phylogroup A and B1 and
Table 1 Primers used for the detection of colicin genes
Colicin Primer Sequention of the primer Lenght of the PCR product
A ColA-F cgtggggaaaagtcatcatc 475
ColA-R gctttgctctttcctgatgc
B colicinB-F aagaaaatgacgagaagacg 492
colicinB-R gaaagaccaaaggctataagg
D ColD-F ctggactgctgctggtgata 420
ColD-R gaaggtgcgcctactactgc
E1 colicinE1-F tgtggcatcgggcgagaata 649
colicinE1-R ctgcttcctgaaaagcctttt
E1-1 cea2F ggtggaactggaggtagcaa 357
ceaR acgtcgttgttctgcttcct
E2 ColE2-F tgatgctgctgcaaaagag 409
ColE2-R ttcaaagcgttccctaccac
E3 ColE3-F taagcaggctgcatttgatg 413
ColE3-R tcggatctggacctttcaac
E4 ColE4-F gaaggctgcatttgatgct 409
ColE4-R cggatccggacctttaattt
E5 ColE3-F taagcaggctgcatttgatg 430
ColE5-R ttgaattctcgaatcgtcca
E6 ColE6-F accgaacgtccaggtgtt 399
ColE6-R tttagcctgtcgctcctgat
E7 ColE7-F gcattctgccatctgaaat 431
ColE7-R cttctgcccactttctttcg
E8 ColE3-F taagcaggctgcatttgatg 449
ColE8-R gactgattggcttgtcgtga
E9 ColE3-F taagcaggctgcatttgatg 418
ColE9-R gacttttctccctccgacct
Ia ColIa-F gcatgcaaatgacgctctta 473
ColIa-R gaggacgccagttctctgtc
Ib ColIb-F aacgagtgggtcgatgattc 464
ColIb-R ccttttctgcgctcgtattc
Js ColJs-F tcaaaatgtttgggctcctc 254
ColJs-R taatctgccctgtcccactg
K ColK-F cagaggtcgctgaacatgaa 469
ColK-R tccgctaaatcctgagcaat
L Col28b(L)-F tgcatattgaaagcgtcagc 449
Col28b(L)-R caggttatcccctctcacca
M ColM-F gcttaccacttcgcaaaacc 429
ColM-R gagcgactctccgataatgc
N ColN-F agcttggcgagtatcttgga 401
ColN-R caacacagccccgaataaac
S4 ColS4-F tatatggcccaactgctggt 456
ColS4-R cgtaaggacggacacctgtt
U ColU-F tgattgctgcgagaaaaatg 485
ColU-R tctgacagcctctccctgtt
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Table 1 Primers used for the detection of colicin genes (Continued)
Colicin Primer Sequention of the primer Lenght of the PCR product
Y ColY-F gcaggcagaaaagaacaagg 477
ColY-R cggacgttatttgccttcat
5 Col5-F cattggcaaaagcgaaatct 443
Col5-R tgcaactctggaaacaatcg
10 Col10-F ggttaccggatttcctggat 448
Col10-R ttctagatgcttggcccact
Fy ColFy-Fa aaattaagcggtgccattgac 580
ColFy-Fa ttctaattgcgccagacctt
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vealed in the patients with CRC. This finding shows that
the large intestinal mucosa of the patients with CRC is
colonized with more virulent E. coli strains. We also
confirmed in our study, that large intestinal mucosa of
patients with CRC is inhabited with a significantly higher
proportion of Escherichia coli strains when compared to
the healthy controls.
E. coli strains of the B2 phylogenetic group harbour
the “pks” genomic island, which encodes production of a
non-ribosomally synthetised polyketide-peptide geno-
toxin, called colibactin [20]. A study carried out by
Cuevas-Ramos et al. documented that even a single
and short exposure of mammalian epithelial cells to
“pks” positive E. coli strains at low infectious doses in-
duced DNA-double strand breaks, signs of incomplete
DNA repair during the cell division which finally lead
to the chromosome aberrations [21]. Infection caused
by “pks” positive E. coli strains affects the host immuneTable 2 Primers used for the detection of microcin genes
Microcin Primer Sequentio
B17 mcc B17-F tcacgccagt
mcc B17-R ttccgccgct
C7 mcc C7-F cgttcaactg
mcc C7-R agttgaggg
E492 mcc E492-F gtctctcctgc
mcc E492-R ttttcagtcat
H47 mcc H47-F cactttcatcc
mcc H47-R agctgaagtc
J25 mcc J25-F tcagccatag
mcc J25-R tgattaagca
L mcc L-F ggtaaatgat
mcc L-R tttcgctgag
V mcc V-F cacacacaaa
mcc V-R tttcgctgag
M micM-4-F cgtttattagc
micM-4-R gcagacgaaresponse and is accompanied by the production of oxygen
species, pro-inflammatory cytokines and protease secre-
tion. These mediators are able to trigger DNA-double
strand breaks [22,23]. Nowrouzian et al. substantiated the
contribution of “pks” island to long-term gut-colonization
of E. coli B2 strains [20]. Association of colonic mucosa of
patients with CRC and enterotoxigenic E. coli belonging
to the B2 phylogroup, which produces toxins called cyclo-
modulins, has been also highlighted recently [24]. Despite
all recent efforts, the precise etiopathogenesis of right-
sided colorectal cancer has not yet been clarified [25]. The
high occurrence of the mutagenic E. coli B2 phylogroup in
our patients with right-sided colorectal cancer could eluci-
date the pathogenesis and difference in the pathways of
cancer development when compared to the patients with
left-sided colorectal cancer. These conclusions are in
agreement with those of Cuevas-Ramos, who assumed
that colon colonization with “pks” positive E. coli strains

















Table 3 Characteristics of large intestinal microbiota, bacteriocins and E. coli phylogroups in each investigated group
of patients/controls
Adenoma Carcinoma Controls
Number of biopsies with ≥1 strain belonging to Enterobacteriaceae family
per all biopsies taken in each group
89/90 (99%) 89/90 (99%) 60/60 (100%)
Bacteriocinogeny 58/89 (65%) 61/89 (69%) 39/60 (65%)
Colicinogeny 31/89 (35%) 40/89 (45%) 24/60 (40%)
Microcinogeny 46/89 (52%) 53/89 (60%) 36/60 (60%)
Simultaneous colicinogeny and microcinogeny 19/89 (21%) 32/89 (36%) 21/60 (35%)
Frequency of E. coli from Enterobacteriaceae strains 77/89 (87%) 87/89 (98%) 48/60 (80%)
E. coli - phylogroup A 31/77 (40%) 30/87 (34%) 21/48 (44%)
E. coli - phylogroup B1 19/77 (25%) 18/87 (21%) 12/48 (25%)
E. coli - phylogroup B2 35/77 (45%) 41/87 (47%) 24/48 (50%)
E. coli - phylogroup D 16/77 (21%) 24/87 (28%) 6/48 (13%)
The details refer to the numbers of biopsies taken in each group of individuals.
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deletion of the “pks” genotoxic island from E. coli NC101
decreased intestinal tumor multiplicity and invasion in ex-
perimental mice, without altering intestinal inflammation
[26]. A higher frequency of E. coli phylogroup B2 in the
patients with advanced CRA when compared to the pa-
tients with non-advanced CRA in our study confirms the
anticipated involvement of “pks” positive E. coli strains in
the pathogenesis of CRC.
The antineoplastic effect of colicins has been described
in in vitro studies: colicin E3 is able to inhibit prolifera-
tion of leukemic cells [27,28] and shows antineoplastic
effect towards HeLa cells, epithelial cells derived from
the cervix [29]. The cytotoxic effect of colicins was also
proven against breast cancer cells [30]. Farkas-Himsley
substantiated in an experimental study, that the cells of
colorectal adenocarcinoma were more sensitive to bacte-
riocins when compared to normal cells of large bowel
mucosa [31]. Bures et al. studied colicin production in
the patients with CRC and found a significantly higher
colicinogeny in the healthy controls when compared to
the patients with CRC [12]. This was not confirmed in
another study performed by Smarda et al. [32]. Our
current study is in agreement with that of Smarda et al.
in that we have not found a difference in bacteriocino-
geny between the patients with CRC and the healthyTable 4 Characterictics of bacteriocinogeny in patients with C
Staging (TNM classification) I
Bactericinogenic strains 6/12 (50%)
Colicinogenic strains 3/12 (25%)
Microcinogenic strains 5/12 (42%)
Strains producing colicin and microcin 2/12 (17%)
Association between increasing bacteriocinogeny, colicinogeny, microcinogeny, col
significant difference was found in microcinogeny between the stage 1 and stage 4controls. However we found a significantly higher si-
multaneous production of colicins and microcins in the
patients with CRC when compared to the patients with
CRA. Patients with advanced CRA had also a statistically
higher bacteriocinogeny when compared to those with
non-advanced CRA. Increasing bacteriocinogeny asso-
ciated with an increasing stage of CRC (when assessed
according to the TNM classification) highlights the
previous findings: there is an increasing bacteriocin
production from non-advanced CRA to advanced CRA
and from non-advanced CRC to advanced CRC. Large
intestinal mucosa of the patients with more advanced
colorectal neoplasia is also colonized with more virulent
strains of Escherichia coli.
We presume that the intermicrobial competition (for
nutrition, etc.) in the large bowel of healthy subjects
can be conveyed as a high simultaneous production of
microcins and colicins. We may hypothetize that if the
production of antimicrobial, antiapoptotic and potentially
antineoplastic bacteriocins decreases in the healthy in-
dividuals, this could co-iniciate the development of a
non-advanced colorectal neoplasia. With the growth,
development and progression of a non-advanced neoplasia
into an advanced one, higher production of bacteriocins is
again identified and also more virulent E. coli strains are
present. We assume, that this situation could be beneficialRC
II III IV
10/12 (83%) 26/38 (68%) 6/6 (100%)
4/12 (33%) 20/38 (53%) 4/6 (67%)
8/12 (67%) 24/38 (63%) 6/6 (100%)
2/12 (17%) 18/38 (47%) 4/6 (67%)
icinogeny & microcinogeny with an increasing stage of CRC. A statistically
: p = 0.038.
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bating the colorectal cancer. Our hypothesis needs furher
investigation especially in the field of potential antineo-
plastic properties of the bacteriocins and clarification of
their interaction with the eukaryotic host.Conclusions
Large intestinal mucosa of the patients with more advanced
colorectal neoplasia is colonized with more virulent strains
of Escherichia coli and a higher production of bacteriocins
is observed in these patients when compared to those with
less advanced colorectal neoplasia.Availability of supporting data
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